Abstract:Background: Aspirin can induce small bowel injury. There is no proven treatment of aspirin enteropathy other than withdrawal. Recently, a novel aspirin associated with phosphatidylcholine(PC) is designed to be gastric protective due to hydrophobic property of PC. Lysophosphatidic acid (LPA), a metabolite from PC and mucin were found to play roles in integrity of gastrointestinal tract epithelium. This study hypothesized that PC-aspirin would reduce aspirin-induced small bowel injury. Methods: Sprague-Dawley rats were intra-duodenally administrated with either PC-aspirin (100mg, n=12-14), Plain aspirin (100mg, n=12-14) or vehicle (1ml 2%methtcellylulose, n=12), and euthanized after 90 minutes. Small bowel injury was assessed by lesion area, vascular permeability (i.v. 1% Evan's blue solution), intestinal hemoglobin concentration and histological change (H&E stained slides were scored with a scoring system). Apoptotic index was estimated with western blot and TUNEL staining (apoptotic cell in 5 villi would be counted). The expressions of lysophosphatidic acid receptor 2 (LPA2), MUC2 the mainly expressed secretory mucin in intestine, and TLR4, MyD88, NF-κΒp50 were test with Western blot or real-time PCR. Mucins were stained with Periodic Acid Schiff (PAS). Prostaglandin E2 (PGE2) concentration were detect with ELISA. Results: Comparing to plain aspirin-treated rats, PC-aspirin caused fewer injuries in the small bowel as assessed in: lesion area (4.82±1.61mm2 vs 196.00±84.89mm2 P=0.003), vascular permeability (42.81±7.69ug/ml vs 74.73±18.61ug/ml P=0.003), intestinal hemoglobin concentration (66.67±16.81ng/ml vs 91.83±14.80ng/ml P=0.020) and histological change (2.12±0.56 vs 3.06±1.07 P=0.044)(Figure 1). Also a decreased apoptotic index was found in PC-aspirin group (16.43±4.28 vs 38.71±5.59 P<0.001 for TUNEL, 0.49±0.14 vs 1.06±0.33 P=0.007 for cleaved caspase-3, 0.81±0.29 vs 1.40±0.56 P=0.043 for cleaved caspase-7, Figure 1). Immunohistochemical staining and western blot (0.21±0.06 vs 0.14±0.06 P=0.044 for PCaspirin vs Plain aspirin) showed that LPA2-positive cells were strongly expressed in surfacelining of small bowel mucosa in the control and PC-aspirin groups but not in the plain aspirin group (Figure 2). Moreover, PAS staining reveals a thicker mucin layer in PC-aspirin rats, with a higher MUC2 mRNA level than plain aspirin rats (1.70±0.75 vs 0.98±0.45 P= 0.039)(Figure 2). The tissue expressions of TLR4, MyD88, NF-κΒp50 and COX-2 were increased while PGE2was decreased in both plain aspirin and PC-aspirin groups. Conclusion: PC-aspirin significantly decreased aspirin induced small bowel injury, this effect may associated with (1) increased LPA2 expression, which protect mucosa from apoptotic damages, and (2) increased MUC2 mRNA expression and decreased mucin layer consumption caused by aspirin, which help to suppress bacterial invasion.

Lactobacillus complex capsules ameliorate aspirin-related small intestinal mucosal injury: a prospective, randomized, controlled clinical trial

Tu1228 Effect of Phosphatidylcholine (PC)-Aspirin on Small Bowel Mucosal Injury

Effect of Weikang Capsule () on Aspirin-Related Gastric and Small Intestinal Mucosal Injury

Effects of Long-term, Low-dose, Enteric-coated Aspirin on Gastroduodenal Mucosa: A Case-control Study

Effect of a proton-pump inhibitor on intestinal microbiota in patients taking low-dose aspirin

[Preventive Effects of Jinghua Weikang Capsule on NSAID-induced Injury to the Mucosa of the Small Intestine: an Experimental Research].

Long-term Aspirin Intervention Can Inhibit TIGIT, Regulating T Cells to Reverse Damage to Intestines.

[Protective Effect of Compound Bismuth and Magnesium Granules on Aspirin-Induced Gastric Mucosal Injury in Rats].

Reduced gastric injury with a novel, liquid lipid-aspirin formulation: results from a pooled, patient level analysis of two randomized endoscopy studies In healthy volunteers

The effect of an acute aspirin challenge on intestinal permeability in healthy adults with and without prophylactic probiotic consumption: a double-blind, placebo-controlled, randomized trial

The Effects of Aspirin Intervention on Inflammation-Associated Lingual Bacteria: A Pilot Study from a Randomized Clinical Trial

Minimization of gastric damage with enteric-coated aspirin granules compared to buffered aspirin.

Fecal 16S rRNA Gene Sequencing Analysis of Changes in the Gut Microbiota of Rats with Low-Dose Aspirin-Related Intestinal Injury

Exploratory plasma proteomic analysis in a randomized crossover trial of aspirin among healthy men and women

Geranylgeranylacetone Protects Against Small-Intestinal Injuries Induced by Diclofenac in Patients with Rheumatic Diseases: A Prospective Randomized Study

Inhibition of Aspirin-Induced Gastrointestinal Injury: Systematic Review and Network Meta-Analysis

IDDF2019-ABS-0188 Gut Microbiota Modulates the Chemopreventive Efficacy of Aspirin on Colorectal Cancer Through Impact on Aspirin Bioavailability

The protective effect of Bifidobacterium bifidum G9-1 against mucus degradation by Akkermansia muciniphila following small intestine injury caused by a proton pump inhibitor and aspirin

Drugs Effective for Nonsteroidal Anti-inflammatory Drugs or Aspirin-induced Small Bowel Injuries: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Aspirin Reduces Colorectal Tumor Development in Mice and Gut Microbes Reduce Its Bioavailability and Chemopreventive Effects.

Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions